ARA-290: Nerve Repair & Pain Relief
A short solo explainer on ARA 290 covering its claimed mechanism, dosing, side effects, and what the host stacks with it, based on the host's own reading.
With Matthew
Key moments
Tap a moment to play the video from there.
- 0:00Intro and disclaimerMatthew frames ARA 290 as a peptide in advanced clinical trials for nerve protection and pain. He states he is not a licensed medical professional.
- 1:03What ARA 290 isHe describes it as a peptide designed from EPO that has passed phase two trials and is moving to phase three, with applications in diabetes, wound healing and autoimmune conditions.
- 1:34The four receptorsHe walks through the four receptors he says it binds and what each is associated with, from tissue protection to immune activation.
- 2:30Listed research benefitsHe lists immune support, nerve protection, anti-inflammatory action, pain modulation, wound healing and blood vessel support.
- 2:53Cautions and active infectionHe mentions nausea, headache and discomfort, and says it is unclear how ARA 290 interacts with an active infection.
- 3:24Dosing and cyclingHe reports 4 to 8 mg per dose in 30-day daily cycles with at least a 30-day break, and says the scheme depends on the goal.
- 4:11Peptides to combineHe names healing, immune and growth hormone peptides he would pair with ARA 290, depending on the goal.
- 5:01Supplements he would addHe suggests collagen or bone broth protein, a mushroom complex, binders such as charcoal, and NAD and glutathione.
- 5:39Lifestyle toolsHe lists diet with fasting, corrective exercise, hot and cold therapy, bodywork and hyperbaric oxygen, and notes diabetics should be careful with sauna and ice baths.
- 6:50Pros, cons and his viewHe gives the phase three progress and nerve pain regulation as pros, and cost as the main con. He says he would reach for it first for nerve or diabetic complications.
What the video says
This is an 8:40 explainer from Matthew on the Peptide Insights channel about ARA 290, a peptide he describes as designed from erythropoietin, or EPO. He opens with a disclaimer that he is not a licensed doctor or medical professional and that the content is for educational and entertainment purposes. He says the peptide has passed phase two clinical trials and is moving to phase three, with applications he lists as diabetes, wound healing and autoimmune conditions.
On mechanism, Matthew says ARA 290 binds four receptors: the tissue protective receptor, the innate repair receptor, the erythropoietin receptor and toll-like receptor 2. He links these to tissue protection, pain modulation, cellular protection and immune activity. The research benefits he lists are immune support, nerve protection and regeneration, anti-inflammatory action, pain modulation, wound healing, and support for blood vessels.
On practical points, he says the most common cautions he has seen are nausea, headache and some discomfort. He names active infection as a possible contraindication, because researchers are unsure whether it would make an infection better or worse. He reports doses of 4 to 8 mg, taken in 30-day daily cycles with a break of at least 30 days. He stresses that the right scheme depends on the goal and that no exact protocol can be given.
About half the video covers what he would combine with ARA 290. His peptide list includes BPC 157, TB 500, GHK-Cu, KPV, LL-37, thymosin alpha-1 and growth hormone combinations. He also covers supplements and lifestyle tools such as a diet based on meat and organ foods with fasting, corrective exercise, hot and cold exposure, lymphatic massage, acupuncture, chiropractic and hyperbaric oxygen. These are his personal preferences, not trial findings. He closes by naming the phase three move and nerve pain regulation as pros and cost as the main con. He calls ARA 290 his first pick for nerve or diabetic complications, while saying he needs to do more research.
On each compound
ARA-2901:03
Matthew describes ARA 290 as an EPO-derived peptide that he says has passed phase two trials and is moving to phase three. He reports 4 to 8 mg doses in 30-day cycles, and nausea, headache and discomfort as the cautions he has seen.
See how your DNA reads ARA-290“it's really hard to give you an exact dosing and cycling scheme”
What this video doesn’t settle
- The video cites no trial data, results or sources, so the phase two and phase three claims and the listed benefits rest on the host's summary alone.
- The dosing and cycling figures are what the host says he has seen, not a studied or established protocol.
- The host says it is unknown how ARA 290 behaves during an active infection, and the side effect list is informal.
Questions this video answers
What dose of ARA 290 does Matthew mention?
Matthew says he has seen 4 to 8 mg per dose, taken daily in 30-day cycles with at least a 30-day break. He adds that this depends on the goal and that he cannot give an exact scheme.
What side effects of ARA 290 does the video mention?
Matthew says the most common cautions he has seen are nausea, headache and some discomfort. He also says active infection is a possible contraindication because researchers are unsure of the effect.
How does ARA 290 work according to this video?
Matthew says it binds four receptors: the tissue protective receptor, the innate repair receptor, the erythropoietin receptor and toll-like receptor 2. He associates these with tissue protection, pain modulation, cellular protection and immune activity.
What clinical trial stage is ARA 290 in, according to Matthew?
He says ARA 290 has passed phase two clinical trials and is moving on to phase three. He cites diabetes, wound healing and autoimmune conditions as areas of application.
Video by Peptide Insights on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
